News Breaks |
|
|
| September 4, 2012 |
| 10:55 EDT |  | AMRN, AMRN, REGN, REGN, BMY, BMY, MRK, MRK, AMGN, AMGN | Summer Street's biotech research team holds analyst/industry conference call
Analyst Research Team discusses novel treatments for increased cholesterol or triglycerides on an Analyst/Industry conference call. Relevant covered companies AMRN, REGN, BMY, MRK and AMGN will be discussed on the Analyst/Industry conference call on September 4 at 11 am. |
|
|
News For AMRN;REGN;BMY;MRK;AMGN From The Last 14 Days Check below for free stories on AMRN;REGN;BMY;MRK;AMGN the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT | | MRK | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:34 EDT | | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 19:01 EDT |  | REGN | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:49 EDT |  | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 17:26 EDT | | REGN | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | REGN | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
|
| 07:28 EDT | | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
| |
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information |
|
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| 10:07 EDT |  | REGN | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:16 EDT | | REGN | Regeneron initiated with a Neutral at UBS
Subscribe for More Information |
|
| 06:33 EDT | | REGN | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
| |
|
|
|
|
